Cargando…
Desidustat in Anemia due to Dialysis-Dependent Chronic Kidney Disease: A Phase 3 Study (DREAM-D)
BACKGROUND: A phase 3 study to assess the efficacy and safety of the desidustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, against the epoetin alfa for the treatment of anemia in patients with chronic kidney disease (CKD) with dialysis dependency. METHODS: DREAM-D was a phase 3,...
Autores principales: | Gang, Sishir, Khetan, Prakash, Varade, Deepak, Chinta, Venkata Ramakrishna, Mavani, Siddharth, Gupta, Umesh, Reddy, S. Venkata Krishna, Rajanna, Sunil, Jeloka, Tarun, Ruhela, Vivek, Kansagra, Kevinkumar, Kanani, Pooja, Bhatt, Jayesh, Zala, Kuldipsinh |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
S. Karger AG
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9254304/ https://www.ncbi.nlm.nih.gov/pubmed/35462369 http://dx.doi.org/10.1159/000523949 |
Ejemplares similares
-
Desidustat: First Approval
por: Dhillon, Sohita
Publicado: (2022) -
Prolyl hydroxylase inhibitor desidustat improves anemia in erythropoietin hyporesponsive state
por: Joharapurkar, Amit A., et al.
Publicado: (2022) -
Association of the novel cardiovascular risk factors paraoxonase 1 and cystatin C in type 2 diabetes
por: Connelly, Philip W., et al.
Publicado: (2009) -
Genome-wide association study of genetic determinants of LDL-c response
to atorvastatin therapy: importance of Lp(a)
por: Deshmukh, Harshal A., et al.
Publicado: (2012) -
Testosterone replacement in hypogonadal men alters the HDL proteome but
not HDL cholesterol efflux capacity
por: Rubinow, Katya B., et al.
Publicado: (2012)